APL1101 / Atransen Pharma - LARVOL DELTA

Development of novel anti-cancer drug by "locking inhibition" of amino acid transporter LAT1. (ASCO 2026) - "APL1101's innovative irreversible LAT1 inhibition mechanism demonstrates robust preclinical efficacy and safety, supporting its potential as a transformative therapy for aggressive cancers. Its versatility as a monotherapy or in combination regimens with chemotherapeutics and immunotherapies offers significant promise for broader cancer treatment. The upcoming clinical trials will provide critical insights into its full therapeutic potential."

IO biomarker • Breast Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer